Tag: Fuels

  • How Higher Education Fuels Big Pharma’s Bottom Line

    How Higher Education Fuels Big Pharma’s Bottom Line

    As public outrage grows over the astronomical cost of prescription drugs, a quieter but equally consequential dynamic demands scrutiny: the entanglement of higher education institutions with the pharmaceutical industry. Universities—especially those with medical schools and biomedical research centers—have become indispensable players in Big Pharma’s pipeline. While these partnerships often promise innovation and public benefit, they also raise troubling questions about academic independence, ethical boundaries, and the commodification of publicly funded science.

    Medical Education: A Curriculum Under Influence

    Medical schools are tasked with training future physicians in evidence-based care. Yet many institutions maintain financial ties with pharmaceutical companies that risk compromising the integrity of their curricula. Faculty members often receive consulting fees, research grants, and honoraria from drug manufacturers. In some cases, industry-sponsored materials and lectures are integrated into coursework, subtly shaping how students understand disease treatment and drug efficacy.

    This influence extends beyond the classroom. Continuing medical education (CME), a requirement for practicing physicians, is frequently funded by pharmaceutical companies. Critics argue that this model incentivizes the promotion of branded drugs over generics or non-pharmaceutical interventions, reinforcing prescribing habits that benefit corporate interests more than patient outcomes.

    University Research: Innovation or Outsourcing?

    Academic research is a cornerstone of pharmaceutical development. Universities conduct early-stage investigations into disease mechanisms, drug targets, and therapeutic compounds—often funded by public grants. Pharmaceutical companies then step in to commercialize promising discoveries, assuming control over clinical trials, regulatory approval, and marketing.

    While this division of labor can accelerate drug development, it also shifts the locus of control. Universities may prioritize research that aligns with industry interests, sidelining studies that lack commercial appeal. Moreover, corporate sponsors can exert influence over publication timelines, data interpretation, and intellectual property rights. The result is a research ecosystem where profit potential increasingly dictates scientific inquiry.

    Case Studies: The University-Pharma Nexus in Action

    Harvard University
    Harvard Medical School has faced scrutiny over the financial relationships between its faculty and pharmaceutical companies. A 2009 investigation by The New York Times revealed that more than 1,600 Harvard-affiliated physicians had financial ties to drug and medical device makers. The controversy sparked student protests and led to reforms requiring faculty to disclose industry ties and limiting pharma-funded materials in classrooms.

    Harvard’s research enterprise is deeply intertwined with Big Pharma. Its partnership with Novartis in developing personalized cancer treatments—particularly CAR-T cell therapy—illustrates how academic science feeds into high-cost commercial therapies. While the treatment represents a breakthrough, its price tag (often exceeding $400,000 per patient) raises questions about the public’s return on investment.

    Yale University
    Yale’s collaboration with GlaxoSmithKline (GSK) on PROTACs (proteolysis-targeting chimeras) showcases the university’s role in pioneering new drug technologies. Under the agreement, Yale and GSK formed a joint research team to advance PROTACs from lab concept to clinical candidate. GSK gained rights to use the technology across multiple therapeutic areas, while Yale stood to receive milestone payments and royalties.

    Yale’s Center for Clinical Investigation (YCCI) saw an 850% increase in industry-sponsored trials between 2006 and 2019. To address concerns about equity, YCCI launched the Cultural Ambassador Program to diversify trial participation. While this initiative promotes inclusivity, it also serves the interests of pharmaceutical sponsors seeking broader demographic data for regulatory approval.

    University of Bristol (UK)
    The University of Bristol has maintained a decade-long partnership with GSK, spanning vaccine development, childhood disease research, and oral health. GSK funds PhD studentships and undergraduate placements and collaborates on data integrity initiatives. While the partnership aims to improve global health outcomes, it also serves GSK’s need to secure early-stage innovation and talent.

    Temple University
    Temple’s Moulder Center for Drug Discovery Research exemplifies the shift toward academic-led drug discovery. Pharmaceutical companies increasingly rely on centers like this to conduct early-stage research, reducing their own financial risk. As patents expire and blockbuster drugs lose exclusivity, pharma firms turn to universities to replenish their pipelines—often with taxpayer-funded science.

    ETH Zurich (Switzerland)
    ETH Zurich has become a hub for synthetic organic and medicinal chemistry, attracting partnerships with major pharmaceutical firms. Researchers at ETH conduct foundational work that pharma companies later commercialize. This reflects a broader trend: the outsourcing of riskier, cost-intensive research to academic institutions, often without proportional public benefit.

    The Dark Legacy of Elite University Medical Centers

    Beyond research and education, elite university medical centers have long been implicated in systemic inequality and exploitation. As detailed in The Dark Legacy of Elite Medical Centers, these institutions have historically treated marginalized and low-income patients as expendable research subjects. The term “Medical Apartheid,” coined by Harriet Washington, captures the racial and class-based exploitation embedded in American medical history.

    The disparities extend to labor conditions as well. Support staff—often immigrants and people of color—face low wages, poor working conditions, and job insecurity, despite being essential to hospital operations. Meanwhile, early-career researchers and postdocs, many from working-class backgrounds, endure long hours and precarious employment while driving the innovation that fuels Big Pharma’s profits.

    Even diversity initiatives at these institutions often fall short, focusing on optics rather than structural reform. As the article argues, “The institutional focus on ‘diversity’ and ‘inclusion’ often overlooks the more significant structural issues, such as the affordability of education, the class-based access to healthcare, and the economic barriers that continue to undermine the ability of disadvantaged individuals to receive quality care.”

    Technology Transfer and Patents: The Profit Pipeline

    Many universities have established technology transfer offices to manage the commercialization of academic discoveries. These offices negotiate licensing agreements with pharmaceutical companies, often securing royalties or equity stakes in exchange. While such arrangements can generate substantial revenue—especially for elite institutions—they also entangle universities in the profit-driven logic of the pharmaceutical market.

    This entanglement has real-world consequences. Drugs developed with public funding and academic expertise are frequently priced out of reach for many patients. The Bayh-Dole Act of 1980, which allows universities to patent federally funded research, was intended to spur innovation. But critics argue it has enabled the privatization of public science, with universities acting as gatekeepers to life-saving treatments.

    Ethical Crossroads: Transparency and Reform

    The growing influence of Big Pharma in higher education has prompted calls for greater transparency and accountability. Some institutions have implemented conflict-of-interest policies, requiring faculty to disclose financial ties and limiting industry-sponsored events. Student-led movements have also emerged, demanding reforms to ensure that education and research serve the public good rather than corporate profit.

    Yet systemic change remains elusive. The financial incentives are substantial, and the boundaries between academia and industry continue to blur. Without robust oversight and a recommitment to academic independence, universities risk becoming complicit in a system that prioritizes shareholder value over human health.

    Rethinking the Role of Higher Ed and Medicine

    Higher education institutions occupy a unique position in society—as centers of knowledge, innovation, and public trust. Their collaboration with Big Pharma is not inherently problematic, but it must be guided by ethical principles and a commitment to transparency. As the cost of healthcare continues to rise, universities must critically examine their role in the pharmaceutical ecosystem and ask whether their pursuit of profit is undermining their mission to serve the public.

    The legacy of elite university medical centers is not just about innovation—it’s also about inequality. Until these institutions confront their role in perpetuating racial and class-based disparities, their contributions to public health will remain compromised.

    Sources:

    • The Dark Legacy of Elite University Medical Centers

    • Harvard T.H. Chan School of Public Health: Pharma and Digital Innovation in China

    • Harvard Business School Case Study: Novartis and Personalized Cancer Treatment

    • Yale Law School: Pharmaceutical Public-Private Partnerships

    • GSK and Yale PROTAC Collaboration Press Release

    • Yale Center for Clinical Investigation Case Study

    • University of Bristol and GSK Case Study

    • Pharmaphorum: Universities and Pharma Companies Need Each Other

    • Chemical & Engineering News: The Great Pharmaceutical-Academic Merger

    Source link

  • Understanding Value of Learning Fuels ChatGPT’s Study Mode

    Understanding Value of Learning Fuels ChatGPT’s Study Mode

    Instead of generating answers, Study Mode asks students questions about what they know.

    Photo illustration by Justin Morrison/Inside Higher Ed | SDI Productions/E+/Getty Images

    When classes resume this fall, college students will have access to yet another generative artificial intelligence tool marketed as a learning enhancement.

    But instead of generating immediate answers, OpenAI’s new Study Mode for ChatGPT acts more like a tutor, firing off questions, hints, self-reflection prompts and quizzes that are tailored to the user and informed by their past chat history. While traditional large language models have raised academic integrity concerns, Study Mode is intended to provide a more active learning experience. It mimics the type of Socratic dialogue students may expect to encounter in a lecture hall and challenges them to draw on information they already know to form their own nuanced analyses of complex questions.

    For example, when Inside Higher Ed asked the traditional version of ChatGPT which factors caused the United States Civil War, it immediately responded that the war had “several major causes, most of which revolved around slavery, states’ rights, and economic differences,” and gave more details about each before producing a five-paragraph essay on the topic. Asking Study Mode the same question, however, prompted it to give a brief overview before asking this question: “Would you say the war was fought because of slavery, or about something else like states’ rights or economics? There’s been debate over this, so I’d love to hear your view first. Then I’ll show you how historians analyze it today.”

    Study Mode is similar to the Learning Mode that Anthropic launched for its chat bot Claude for Education back in April and the Guided Learning version of Gemini that Google unveiled Wednesday. OpenAI officials say they hope Study Mode will “support deeper learning” among college students.

    While teaching and learning experts don’t believe such tools can replace the value faculty relationships and expertise offer students, Study Mode’s release highlights generative AI’s evolving possibilities—and limitations—as a teaching and learning aid. For students who choose to use it instead of asking a traditional LLM for answers, Study Mode offers an on-demand alternative to a human tutor, unbound by scheduling conflicts, payment or feedback delays.

    But in an economy where generative AI’s ability to gather and regurgitate information is threatening the future of entry-level office jobs, students will need to understand what they’re trying to get out of their college coursework if they want Study Mode to deliver on its promise to foster deeper learning.

    “Over all, it does represent a significant departure from how people are normally encouraged to use generative AI, given that the value proposition of this technology is largely couched in the concept of efficiency, speed and offloading things that are not as important,” said Trey Conatser, assistant provost for teaching and learning at the University of Kentucky and director of UK’s Center for the Enhancement of Teaching and Learning. “But Study Mode actually asks us to stick with it for it to work, take some time to sit with the friction of learning and be patient with the practice and feedback.”

    Critical Thinking in Age of AI

    The release of Study Mode comes nearly three years after the debut of ChatGPT—and the many other large language models that have followed—set off ongoing concerns among educators that college students’ increased reliance on traditional LLMs to write papers or solve math problems may erode their critical thinking skills.

    There’s not yet a consensus on if generative AI helps or hurts critical thinking, but at least two studies published in the last year found that adults, including college students, who use LLMs to research and learn about a subject exhibited weaker reasoning and analytical skills. And those may be the exact types of skills the roughly two-thirds who are already using generative AI tools like ChatGPT will need to make Study Mode reach its full potential.

    While ChatGPT’s Study Mode is programmed to query students rather than generate answers, the users themselves also need to be prepared to push the LLM to ask deeper, more nuanced questions. At least, that was Conatser’s experience when he tested out Study Mode over the weekend and asked it to help him study for a hypothetical quiz on Romantic poets from 1780 to 1820.

    First, the LLM asked him more about his education level and the focus of the quiz. He told it that he’s a college junior whose quiz will focus on historical context and specified that he wanted help studying William Wordsworth’s poem “The Prelude.”

    The following conversation, which Conatser shared with Inside Higher Ed, ensued:

    Study Mode: Wordsworth described “The Prelude” as “a poem on the growth of my own mind.” What exact subtitle did he eventually attach to the poem that captures this idea?

    (Give it a try, and we’ll check your answer before moving on.)

    Conatser: That’s not so much what I will need to answer. It will be open book, but I will be asked to provide some interpretations to historical context and literary traditions.

    After some more dialogue asking Study Mode to focus on historical context, it generated the following question:

    Study Mode: “Bliss was it in that dawn to be alive …” Based on that word, “bliss,” what general emotion do you think he felt when he first encountered the early French Revolution—excitement, fear or apathy?

    Conatser: That seems like an obvious question

    Study Mode: Understood—let’s turn up the difficulty. In “The Prelude” (Book X), Wordsworth writes of “how in my heart a dreary weight / Fell, and I turned away …”—a moment that marks his break with the revolution he once celebrated.

    Question (one step): Which single, headline-making event in France during 1793 does this passage point to, and why did that event feel like a betrayal of the revolution’s original ideals for many sympathetic British observers?

    Although it took some prodding to get the LLM to ask the type of questions Conatser wanted to see, “I’m still in the driver’s seat with Study Mode,” he said. “That’s where students are going to need to be when they’re using it.”

    Knowing when to push back against Study Mode when it’s not asking the types of questions that will help students master material will be key to helping them get the most out of its ability to foster critical thinking, Conatser said.

    “If someone is going to be totally passive with Study Mode, it may not drive them to where they need to go and they’ll still need to be thinking about how they’re supposed to be studying, what kind of assessment they’re leading up to and what kinds of skills will be more important for that assessment,” he said. “If you don’t know what you don’t know, then you won’t be very effective at using these tools even if they have the types of guardrails that Study Mode has.”

    And if a student isn’t motivated to use Study Mode to its full potential, they can prompt it to generate complete answers, just like a traditional LLM, according to Christian Carmody, a senior researcher at the Research Institute for Learning and Development, who also tested it out this week.

    “For a current events assignment, I prompted Study Mode right away and told it, ‘Before we engage, I do not want your help with this or [to] encourage me to think through this. I do this on my own another time. I really just want the answers,’” Carmody recalled. “It did exactly that.”

    The ability for students to easily manipulate Study Mode could add more pressure to colleges and universities that are facing growing skepticism from students about the value of degrees in the age of AI.

    “Students should be able to think about why learning is valuable to them and why they should be able to engage with material in a way that’s challenging and force deep thinking,” he said. “Until a student has that mindset, I’m not confident that they are going to use this study and learning tool in the way it’s intended to be used.”

    Source link